<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: Discussion of clinical symptoms and differential diagnosis of <z:hpo ids='HP_0000643'>blepharospasm</z:hpo> and treatment with botulinum A toxin </plain></SENT>
<SENT sid="1" pm="."><plain><z:hpo ids='HP_0000643'>Blepharospasm</z:hpo> is an involuntary spasmodic contraction of the eyelids </plain></SENT>
<SENT sid="2" pm="."><plain>Within a few years 35%-70% of the patients becomes severely disabled </plain></SENT>
<SENT sid="3" pm="."><plain>DESIGN: Prospective, open study </plain></SENT>
<SENT sid="4" pm="."><plain>SETTING: Academical Medical Centre, Amsterdam </plain></SENT>
<SENT sid="5" pm="."><plain>METHOD: In the period 1985-1992 we have seen 85 patients with <z:hpo ids='HP_0000643'>blepharospasm</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>Of these 69 were treated with botulinum toxin, a total of 436 treatments, with a mean dose of 25 IU for each eye </plain></SENT>
<SENT sid="7" pm="."><plain>RESULTS: The cause of <z:hpo ids='HP_0000643'>blepharospasm</z:hpo> was unknown in 71 patients </plain></SENT>
<SENT sid="8" pm="."><plain>Secondary <z:hpo ids='HP_0000643'>blepharospasm</z:hpo> occurred in: peripheral <z:hpo ids='HP_0010628'>facial palsy</z:hpo> (one patient), <z:e sem="disease" ids="C0019360" disease_type="Disease or Syndrome" abbrv="ZONA">herpes zoster infection</z:e> of the trigeminal nerve (2), brain <z:mpath ids='MPATH_124'>infarct</z:mpath> (1), use of <z:chebi fb="25" ids="35476">neuroleptics</z:chebi> (2), <z:e sem="disease" ids="C0038868" disease_type="Disease or Syndrome" abbrv="PSNP1">progressive supranuclear palsy</z:e> (2), <z:e sem="disease" ids="C0037019" disease_type="Disease or Syndrome" abbrv="">Shy-Drager syndrome</z:e> (1), <z:hpo ids='HP_0001343'>kernicterus</z:hpo> (1), and morbus <z:e sem="disease" ids="C1527336" disease_type="Disease or Syndrome" abbrv="">Sj√∂gren</z:e> (4) </plain></SENT>
<SENT sid="9" pm="."><plain>There were 18 patients with <z:hpo ids='HP_0002960'>autoimmune diseases</z:hpo> </plain></SENT>
<SENT sid="10" pm="."><plain>77 (91%) patients had a (very) severe form of <z:hpo ids='HP_0000643'>blepharospasm</z:hpo> </plain></SENT>
<SENT sid="11" pm="."><plain>Electromyographic registration revealed a dysfunction of M. levator palpebrae in 7 patients </plain></SENT>
<SENT sid="12" pm="."><plain>More than 70% of the patients were free of symptoms for a mean period of two months after each treatment </plain></SENT>
<SENT sid="13" pm="."><plain>Local side effects were seen in 61 (14%) of the 436 treatments: <z:hpo ids='HP_0000508'>ptosis</z:hpo>, haematoma, <z:mp ids='MP_0001337'>dry eyes</z:mp>, and <z:hpo ids='HP_0000651'>diplopia</z:hpo> </plain></SENT>
<SENT sid="14" pm="."><plain>CONCLUSION: <z:hpo ids='HP_0000643'>Blepharospasm</z:hpo> is a <z:e sem="disease" ids="C0596452" disease_type="Disease or Syndrome" abbrv="">disabling disease</z:e> and occurs sometimes in association with other neurological and ophthalmological diseases </plain></SENT>
<SENT sid="15" pm="."><plain>Botulinum A toxin is a safe and effective therapy </plain></SENT>
<SENT sid="16" pm="."><plain>Electrophysiological investigation is important in the differential diagnosis; it is unnecessary to do CT or MRI routinely </plain></SENT>
</text></document>